Scheduled to open in 2021, the new center will study the therapeutic potential of MDMA, psilocybin, DMT, and mescaline.
Eleusis’s Phase I Alzheimer’s Trial Finds Favorable Safety & Tolerability of LSD in Older Volunteers
There were no abnormalities or deviations in safety or cognitive outcome measures compared to the baseline data.
New research suggests that ketamine can aid in reorganizing alcohol-related memories.
Some changes occured to biomarkers for stress and inflammation. The subjective effects reveal more evidence of the entourage effect.
Psychedelics disrupt the brain networks responsible for the feeling of selfhood.
Real-time gathering of physiological data and subjective effects give clues that may help define a microdose of psilocybin.
Usona Follows COMPASS in Receiving Breakthrough Therapy Designation for Psilocybin to Treat Depression
This means the FDA will work to expedite the development and review of psilocybin so it can get to patients with major depressive disorder as soon as possible.
Usona Institute Beginning Phase 2 Clinical Trials Using Psilocybin to Treat Major Depressive Disorder
Enrollment of study volunteers is expected to start within the next two months.
The center is the first of its kind in the US and will propel psychedelic research to a new level.
Anorexia has phenomenological parallels to anxiety and addiction, both of which have been shown to improve with psilocybin-assisted interventions.